Medindia covers Australia's warnings on unapproved peptides, including a counterfeit retatrutide case where testing turned up a different drug than the label.
Recap by typeshit. Full story at Medindia.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
19:08
A physician on YouTube makes the case that GLP-1 drugs like Ozempic and Mounjaro, plus trial drug retatrutide, are misunderstood when framed as weight loss drugs.
Icotrokinra became the first approved oral IL23 receptor blocker, and a trial found tirzepatide plus ixekizumab gave deeper responses.
Loading…